Earnings Feed
Start Free
Home/Filings/4/A/0000950170-24-016541
4/A//SEC Filing

LEVITT MICHAEL J 4/A

Accession 0000950170-24-016541

CIK 0001839341other
View on SEC.govCompany Profile

Filed

Feb 15, 7:00 PM ET

Accepted

Feb 16, 5:14 PM ET

Size

83.8 KB

Accession

0000950170-24-016541

Insider Transaction Report

Form 4/AAmended
Period: 2024-01-23
Core Scientific, Inc./txCORZ
LEVITT MICHAEL J
DirectorChief Executive Officer
Transactions
  • Disposition to Issuer

    Common Stock, par value $0.0001 per share

    2024-01-23−20,094,478→ 0 total
  • Disposition to Issuer

    Common Stock, par value $0.0001 per share

    2024-01-23−800,210→ 0 total(indirect: See Footnote)
  • Award

    Common Stock, par value $0.00001 per share

    2024-01-23+4,147→ 4,147 total(indirect: See Footnote)
  • Disposition to Issuer

    Common Stock, par value $0.0001 per share

    2024-01-23−3,835,368→ 0 total(indirect: See Footnote)
  • Award

    Common Stock, par value $0.00001 per share

    2024-01-23+30,555→ 34,702 total(indirect: See Footnote)
  • Award

    Common Stock, par value $0.00001 per share

    2024-01-23+86,911→ 86,911 total(indirect: See Footnote)
  • Award

    Tranche 1 Warrants

    2024-01-23+2,691,900→ 2,691,900 total(indirect: See Footnote)
    Exercise: $6.81Exp: 2027-01-23→ Common Stock, par value $0.00001 per share (2,691,900 underlying)
  • Award

    Tranche 1 Warrants

    2024-01-23+810,232→ 810,232 total(indirect: See Footnote)
    Exercise: $6.81Exp: 2027-01-23→ Common Stock, par value $0.00001 per share (810,232 underlying)
  • Disposition to Issuer

    Common Stock, par value $0.0001 per share

    2024-01-23−41,470→ 0 total(indirect: See Footnote)
  • Disposition to Issuer

    Common Stock, par value $0.0001 per share

    2024-01-23−869,110→ 0 total(indirect: See Footnote)
  • Disposition to Issuer

    Common Stock, par value $0.0001 per share

    2024-01-23−10,629,668→ 0 total(indirect: See Footnote)
  • Award

    Common Stock, par value $0.00001 per share

    2024-01-23+2,009,448→ 2,009,448 total
  • Award

    Common Stock, par value $0.00001 per share

    2024-01-23+35,233→ 122,144 total(indirect: See Footnote)
  • Award

    Common Stock, par value $0.00001 per share

    2024-01-23+248,656→ 632,193 total(indirect: See Footnote)
  • Award

    Common Stock, par value $0.00001 per share

    2024-01-23+1,062,967→ 1,062,967 total(indirect: See Footnote)
  • Award

    Common Stock, par value $0.00001 per share

    2024-01-23+430,873→ 1,493,840 total(indirect: See Footnote)
  • Award

    Tranche 2 Warrants

    2024-01-23+183,414→ 183,414 total(indirect: See Footnote)
    Exercise: $0.01Exp: 2029-01-23→ Common Stock, par value $0.00001 per share (183,414 underlying)
  • Award

    Tranche 2 Warrants

    2024-01-23+2,243,253→ 2,243,253 total(indirect: See Footnote)
    Exercise: $0.01Exp: 2029-01-23→ Common Stock, par value $0.00001 per share (2,243,253 underlying)
  • Award

    Tranche 2 Warrants

    2024-01-23+675,195→ 675,195 total(indirect: See Footnote)
    Exercise: $0.01Exp: 2029-01-23→ Common Stock, par value $0.00001 per share (675,195 underlying)
  • Award

    Common Stock, par value $0.00001 per share

    2024-01-23+86,911→ 86,911 total(indirect: See Footnote)
  • Award

    Common Stock, par value $0.00001 per share

    2024-01-23+383,537→ 383,537 total(indirect: See Footnote)
  • Award

    Common Stock, par value $0.00001 per share

    2024-01-23+80,021→ 80,021 total(indirect: See Footnote)
  • Award

    Tranche 1 Warrants

    2024-01-23+2,237,057→ 2,237,057 total
    Exercise: $6.81Exp: 2027-01-23→ Common Stock, par value $0.00001 per share (2,237,057 underlying)
  • Award

    Tranche 1 Warrants

    2024-01-23+220,097→ 220,097 total(indirect: See Footnote)
    Exercise: $6.81Exp: 2027-01-23→ Common Stock, par value $0.00001 per share (220,097 underlying)
  • Disposition to Issuer

    Common Stock, par value $0.0001 per share

    2024-01-23−869,110→ 0 total(indirect: See Footnote)
  • Disposition to Issuer

    Common Stock, par value $0.0001 per share

    2024-01-23−3,199,414→ 0 total(indirect: See Footnote)
  • Award

    Common Stock, par value $0.00001 per share

    2024-01-23+85,355→ 2,094,803 total
  • Award

    Tranche 1 Warrants

    2024-01-23+202,648→ 202,648 total(indirect: See Footnote)
    Exercise: $6.81Exp: 2027-01-23→ Common Stock, par value $0.00001 per share (202,648 underlying)
  • Award

    Tranche 2 Warrants

    2024-01-23+1,864,217→ 1,864,217 total
    Exercise: $0.01Exp: 2029-01-23→ Common Stock, par value $0.00001 per share (1,864,217 underlying)
  • Award

    Tranche 2 Warrants

    2024-01-23+8,752→ 8,752 total(indirect: See Footnote)
    Exercise: $0.01Exp: 2029-01-23→ Common Stock, par value $0.00001 per share (8,752 underlying)
  • Award

    Common Stock, par value $0.00001 per share

    2024-01-23+35,233→ 122,144 total(indirect: See Footnote)
  • Award

    Common Stock, par value $0.00001 per share

    2024-01-23+319,941→ 319,941 total(indirect: See Footnote)
  • Award

    Tranche 1 Warrants

    2024-01-23+10,502→ 10,502 total(indirect: See Footnote)
    Exercise: $6.81Exp: 2027-01-23→ Common Stock, par value $0.00001 per share (10,502 underlying)
  • Award

    Tranche 1 Warrants

    2024-01-23+220,097→ 220,097 total(indirect: See Footnote)
    Exercise: $6.81Exp: 2027-01-23→ Common Stock, par value $0.00001 per share (220,097 underlying)
  • Award

    Tranche 1 Warrants

    2024-01-23+971,284→ 971,284 total(indirect: See Footnote)
    Exercise: $6.81Exp: 2027-01-23→ Common Stock, par value $0.00001 per share (971,284 underlying)
  • Award

    Tranche 2 Warrants

    2024-01-23+183,414→ 183,414 total(indirect: See Footnote)
    Exercise: $0.01Exp: 2029-01-23→ Common Stock, par value $0.00001 per share (183,414 underlying)
  • Award

    Common Stock, par value $0.00001 per share

    2024-01-23+129,704→ 449,645 total(indirect: See Footnote)
  • Award

    Tranche 2 Warrants

    2024-01-23+809,405→ 809,405 total(indirect: See Footnote)
    Exercise: $0.01Exp: 2029-01-23→ Common Stock, par value $0.00001 per share (809,405 underlying)
  • Award

    Tranche 2 Warrants

    2024-01-23+168,874→ 168,874 total(indirect: See Footnote)
    Exercise: $0.01Exp: 2029-01-23→ Common Stock, par value $0.00001 per share (168,874 underlying)
Footnotes (14)
  • [F1]On December 21, 2022, Core Scientific, Inc. (the "Issuer") and certain of its affiliates (collectively, the "Debtors") filed voluntary petitions (the "Chapter 11 Cases") in the United States Bankruptcy Court for the Southern District of Texas (the "Bankruptcy Court") seeking relief under Chapter 11 of Title 11 of the United States Code. On January 16, 2024, the Bankruptcy Court entered an order confirming the Debtors' Fourth Amended Joint Chapter 11 Plan of Reorganization of Core Scientific, Inc. and its Affiliated Debtors (with Technical Modifications) (the "Plan"), dated as of January 15, 2024. On January 23, 2024 (the "Effective Date"), the Plan became effective in accordance with its terms and the Debtors emerged from the Chapter 11 Cases.
  • [F10]The securities are held by Michael J. Levitt and Christopher B. Harrison as Co-Trustees of the MJL 2012 Older Children Trust, modified as of March 21, 2021, which the Reporting Person serves as a trustee.
  • [F11]The securities are held by Michael J. Levitt and Nadine Bernecker Levitt as Co-Trustees of the CS 1219 Trust, dated April 13, 2017, which the Reporting Person serves as a trustee.
  • [F12]The securities are held by Michael J. Levitt, as Trustee of the MJL Revocable Trust, modified as of June 18, 2021, which the Reporting Person serves as a trustee.
  • [F13]The securities are held by Nadine Bernecker Levitt as Trustee of the NBL Revocable Trust, modified as of June 18, 2021, which the Reporting Person serves as a trustee.
  • [F14]The securities are held by MJL Blockchain LLC, which the Reporting Person serves as its managing member.
  • [F2]On the Effective Date, pursuant to the terms of the Plan, the Issuer's common stock outstanding immediately before the Effective Date, par value $0.0001 per share (the "Old Common Stock"), was canceled and is of no further force or effect, and in exchange all holders of Old Common Stock and unvested restricted stock units ("RSUs") received new common stock, par value $0.00001 per share at an exchange ratio of 10:1 (the "New Common Stock") representing, in the aggregate, approximately 21% of the shares of the reorganized Issuer (subject to dilution by awards issuable under a new management incentive plan and shares of New Common Stock issuable upon conversion or exercise of certain secured convertible notes, warrants, contingent value rights and settlement shares issued as part of the reorganization), and, for each share of Old Common Stock, 0.253244 Tranche 1 Warrants and 0.211037 Tranche 2 Warrants (each as defined below).
  • [F3](Continued from footnote 2) The receipt of the New Common Stock, Tranche 1 Warrants and Tranche 2 Warrants in exchange for Old Common Stock and unvested RSUs was involuntary, without consideration and in accordance with the Plan approved by the Bankruptcy Court.
  • [F4]In accordance with the Plan, holders of the Issuer's Old Common Stock as of November 16, 2023 were granted the right to participate in a rights offering (the "Rights Offering") for the purchase, on a pro rata basis, of up to $55 million of New Common Stock to be issued pursuant to the Plan. The Reporting Person purchased an aggregate of 910,254 shares of New Common Stock indirectly pursuant to the Rights Offering.
  • [F5]Certain members of the Issuer's board of directors and management, including the Reporting Person, committed to purchase a portion of any New Common Stock not otherwise subscribed for in the Rights Offering pursuant to a backstop commitment letter (the "Backstop Commitment Letter"). The Reporting Person did not purchase any New Common Stock under the Backstop Commitment Letter, but received a commitment premium of 85,355 shares of New Common Stock as consideration for entering into the Backstop Commitment Letter.
  • [F6]On the Effective Date, pursuant to the terms of the Plan, the Issuer entered into a warrant agreement dated as of January 23, 2024, (the "Warrant Agreement") among the Company and Computershare Inc., a Delaware corporation and its affiliate, Computershare Trust Company, N.A., a federally chartered trust company. Pursuant to the Warrant Agreement, the Issuer was authorized to issue (i) an aggregate of 98,381,418 warrants, each exercisable for one share of New Common Stock (the "Tranche 1 Warrants") and (ii) an aggregate of 81,984,644 warrants, each exercisable for one share of New Common Stock (the "Tranche 2 Warrants"). Each whole Tranche 1 Warrant entitles the registered holder to purchase one whole share of New Common Stock at an exercise price of $6.81 per share (the "Tranche 1 Exercise Price").
  • [F7](Continued from footnote 6) Each whole Tranche 2 Warrant entitles the registered holder to purchase one whole share of New Common Stock at an exercise price of $0.01 per share at any time following the time the volume weighted average price per share of New Common Stock equals or exceeds $8.72 per share on each trading day for 20 consecutive trading days (the "TEV Triggering Event"). The Tranche 1 Exercise Price and the price per share used to determine a TEV Triggering Event are subject to certain adjustments as set forth in the Warrant Agreement.
  • [F8]The securities are held by HKM Investments, LLC, which the Reporting Person serves as its managing member.
  • [F9]The securities are held by Michael J. Levitt, Christopher B. Harrison, and Nadine Bernecker Levitt as Co-Trustees of the MJL 2012 Younger Children Trust, modified as of March 21, 2021, which the Reporting Person serves as a trustee.

Documents

1 file

Issuer

Core Scientific, Inc./tx

CIK 0001839341

→
Entity typeother

Related Parties

1
  • filerCIK 0001228160

Filing Metadata

Form type
4/A
Filed
Feb 15, 7:00 PM ET
Accepted
Feb 16, 5:14 PM ET
Size
83.8 KB
View on SEC.gov